Guest appearance

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Retrieved on: 
Thursday, December 15, 2022
Movement, Diagnosis, Drug discovery, Human, Movement disorders, MDS, Guest appearance, Cros, Moca, Critical path, Clinical, Research, Biomarker, PGI, Patient, CGI, Medical imaging

This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.

Key Points: 
  • This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.
  • By adopting Clinical ink’s BrainBaselineä platform, researchers are now able to access essential insights into Parkinson’s disease progression via remotely monitored sensor biometrics and wearable data collected passively and during fit-for-purpose active tasks.
  • Clinical ink is the global life science company that brings data, technology, and patient science together.
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Retrieved on: 
Wednesday, December 14, 2022
Movement, Diagnosis, Drug discovery, Human, Movement disorders, MDS, Guest appearance, Cros, Moca, Critical path, Clinical, Research, Biomarker, PGI, Patient, CGI, Medical imaging

This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.

Key Points: 
  • This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.
  • By adopting Clinical ink’s BrainBaselineä platform, researchers are now able to access essential insights into Parkinson’s disease progression via remotely monitored sensor biometrics and wearable data collected passively and during fit-for-purpose active tasks.
  • Clinical ink is the global life science company that brings data, technology, and patient science together.
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

Medidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient Experience

Retrieved on: 
Tuesday, December 6, 2022
Science, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Technology, Apps, Applications, Cloud, SOLIDWORKS, CATIA, DELMIA, Learning, Patient, BYOD, Dassault Group, Translation, Research, 3D, Cros, Android, SIMULIA, Clinical trial, IOS, Euronext Paris, Guest appearance, Medical device, Medidata Solutions, ENOVIA, Compass, GEOVIA, BIOVIA

The app will feature all of the myMedidata patient-centric solutions, with an initial focus on eCOA (electronic clinical outcome assessments).

Key Points: 
  • The app will feature all of the myMedidata patient-centric solutions, with an initial focus on eCOA (electronic clinical outcome assessments).
  • Medidata is leveraging its unique insights from sponsors, CROs, sites, and patients to make a meaningful difference in the clinical trial experience.
  • The app is configured using Medidata Designer, a new platform configuration tool, bringing a patient-centered mobile-first workflow builder to the myMedidata app.
  • Designer drastically lowers study build times by employing Medidata and client libraries, including pre-built eCOA instruments, translations, and study configurations.

Graciela Racaro Joins Signant Health as Chief Operating Officer

Retrieved on: 
Thursday, December 8, 2022
Clinical trial, Cros, Drug development, Health, Science, Guest appearance, Research, Growth, Fine chemical

PHILADELPHIA, Dec. 8, 2022 /PRNewswire/ -- Signant Health , the leader in evidence generation for modern clinical trials, announced today the appointment of Graciela Racaro to the position of chief operating officer.

Key Points: 
  • PHILADELPHIA, Dec. 8, 2022 /PRNewswire/ -- Signant Health , the leader in evidence generation for modern clinical trials, announced today the appointment of Graciela Racaro to the position of chief operating officer.
  • A seasoned leader in global clinical development, Racaro will leverage substantial clinical operations and regulatory expertise to drive operational efficiency at scale and deliver exceptional customer experiences.
  • "This is an exciting time to join Signant," noted Racaro of her appointment.
  • Racaro joins Signant following a distinguished 18-year tenure with a leading global clinical research organization (CRO).

Graciela Racaro Joins Signant Health as Chief Operating Officer

Retrieved on: 
Thursday, December 8, 2022
Clinical trial, Cros, Drug development, Health, Science, Guest appearance, Research, Growth, Fine chemical

PHILADELPHIA, Dec. 8, 2022 /PRNewswire/ -- Signant Health , the leader in evidence generation for modern clinical trials, announced today the appointment of Graciela Racaro to the position of chief operating officer.

Key Points: 
  • PHILADELPHIA, Dec. 8, 2022 /PRNewswire/ -- Signant Health , the leader in evidence generation for modern clinical trials, announced today the appointment of Graciela Racaro to the position of chief operating officer.
  • A seasoned leader in global clinical development, Racaro will leverage substantial clinical operations and regulatory expertise to drive operational efficiency at scale and deliver exceptional customer experiences.
  • "This is an exciting time to join Signant," noted Racaro of her appointment.
  • Racaro joins Signant following a distinguished 18-year tenure with a leading global clinical research organization (CRO).

Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program

Retrieved on: 
Wednesday, December 7, 2022
Clinical data management, Data management, IRT, Early adopter, Central nervous system, NPS, Plague, Patient, Translation, Cros, Multimedia, Clinical trial, OR, Guest appearance, CNS, Pharmaceutical industry, Medical device, Medical imaging

PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease, today announced that as part of its single platform rollout, its electronic clinical outcome assessments (eCOA) solution is moving to the second phase of the Early Adopter program. This solution, designed to work seamlessly with Suvoda IRT and eConsent, focuses on tackling the historical inefficiencies that continue to plague eCOA, such as gaps in overall delivery and execution quality, time consuming translations and localization processes, and logistics related to device management.

Key Points: 
  • "In support of Suvoda's mission to enhance the clinical trial process, Suvoda did not want to simply offer another eCOA solution.
  • Within it, Suvoda offers a proprietary domain-specific language and creation tool that is tailor-made for eCOA questionnaires.
  • Questionnaires also can be defined, adjusted, translated, validated, and reused across modalities and devices, all in a regulatory-compliant environment.
  • Suvoda is still accepting participants in the Early Adopter program as eCOA moves into the next phase.

Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program

Retrieved on: 
Wednesday, December 7, 2022
Clinical data management, Data management, IRT, Early adopter, Central nervous system, NPS, Plague, Patient, Translation, Cros, Clinical trial, OR, Guest appearance, CNS, Pharmaceutical industry, Medical device, Medical imaging

PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease, today announced that as part of its single platform rollout, its electronic clinical outcome assessments (eCOA) solution is moving to the second phase of the Early Adopter program. This solution, designed to work seamlessly with Suvoda IRT and eConsent, focuses on tackling the historical inefficiencies that continue to plague eCOA, such as gaps in overall delivery and execution quality, time consuming translations and localization processes, and logistics related to device management.

Key Points: 
  • "In support of Suvoda's mission to enhance the clinical trial process, Suvoda did not want to simply offer another eCOA solution.
  • Within it, Suvoda offers a proprietary domain-specific language and creation tool that is tailor-made for eCOA questionnaires.
  • Questionnaires also can be defined, adjusted, translated, validated, and reused across modalities and devices, all in a regulatory-compliant environment.
  • Suvoda is still accepting participants in the Early Adopter program as eCOA moves into the next phase.

WCG's New Seizure eDiary Optimizes Data Collection and Simplifies the Participant Experience

Retrieved on: 
Tuesday, November 29, 2022
Guest appearance, Epilepsy, BYOD, Seizure, Cros, Hand, Multimedia, Partnership, Health, Caregiver, MBA, Patient, IRB, TESC, WCG, Pharmaceutical industry

WCG is one of two providers selected to develop an eDiary by The Epilepsy Study Consortium.

Key Points: 
  • WCG is one of two providers selected to develop an eDiary by The Epilepsy Study Consortium.
  • The eDiary also provides primary investigators with visibility into a participant's seizure counts when not in clinic.
  • The Seizure eDiary is a key component of WCG's eCOA solution .
  • "A new seizure eDiary optimized for clinical trials will help us accelerate the development of new therapies in epilepsy and improve patient care.

Clinical ink Again Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™

Retrieved on: 
Wednesday, November 16, 2022
Growth, Arthur Seguin, Human, ESourcing Capability Model, Guest appearance, Cros, Patient, Deloitte Technology Fast 500, Biomarker, Science and technology in Asia, Telecommunication, Immunology, Neurology, Medical imaging, Pharmaceutical industry

Horsham, Pennsylvania, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Horsham, Pennsylvania; November 16, 2022 Clinical ink , a global life science technology company, today announced its second consecutive listing on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.

Key Points: 
  • Horsham, Pennsylvania, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Horsham, Pennsylvania; November 16, 2022 Clinical ink , a global life science technology company, today announced its second consecutive listing on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.
  • Seguine said, At Clinical ink, we are committed to powering patient outcomes by converging data, technology, and patient science.
  • Our appearance on the respected Deloitte Technology Fast 500 list for two straight years is direct evidence of our growth and financial performance.
  • Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies both public and private in North America.

eClinical Solutions Will be $22.35 Billion Market by 2030, Says P&S Intelligence

Retrieved on: 
Tuesday, November 22, 2022
Growth, Drug development, Cros, Government, Data management, Guest appearance, Research, Patient, Clinical data management, III, Renewable energy, Pharmaceutical industry, Fine chemical

Moreover, fewer logistical difficulties and the standardization of guidelines are contributing to the increasing count of clinical trials in emerging economies.

Key Points: 
  • Moreover, fewer logistical difficulties and the standardization of guidelines are contributing to the increasing count of clinical trials in emerging economies.
  • eClinical solutions are needed for studying the data generated during the study, in order to reduce the chances of human error.
  • Browse detailed report on eClinical Solutions Market Size, Share, Trends and Growth Analysis 2022-2030
    Moreover, in 2021, the CROs category held the largest share, ascribed to the increasing usage of eClinical solutions for research in the pharmaceutical industry.
  • Therefore, the number of CROs is snowballing in these regions, thus driving the demand for eClinical solutions here.